Drug intelligence / Profile preview

VDA-002

Development stage: Preclinical
Lead developer: viDA Therapeutics
Modality: Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

VDA-002 is a preclinical-stage drug candidate developed by viDA Therapeutics. It acts as a modulator of granzyme K (GZMK), an enzyme implicated in immune system function and inflammation. The primary therapeutic focus for VDA-002 is the treatment of immune system diseases, leveraging its mechanism as a GZMK modulator to potentially regulate immune responses[1][4]. As of the latest updates, it has not entered clinical trials and remains in preclinical development.

Targets

GZMK (Granzyme K)

Beyond the preview

Go deeper on VDA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDA-002.

Explore the full profile